223 related articles for article (PubMed ID: 34330303)
1. Chronotype: what role in the context of gastroenteropancreatic neuroendocrine tumors?
Barrea L; Muscogiuri G; Pugliese G; Modica R; Laudisio D; Aprano S; Faggiano A; Colao A; Savastano S
J Transl Med; 2021 Jul; 19(1):324. PubMed ID: 34330303
[TBL] [Abstract][Full Text] [Related]
2. Cardio-Metabolic Indices and Metabolic Syndrome as Predictors of Clinical Severity of Gastroenteropancreatic Neuroendocrine Tumors.
Barrea L; Muscogiuri G; Modica R; Altieri B; Pugliese G; Minotta R; Faggiano A; Colao A; Savastano S
Front Endocrinol (Lausanne); 2021; 12():649496. PubMed ID: 33815296
[TBL] [Abstract][Full Text] [Related]
3. Impact of Nutritional Status on Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) Aggressiveness.
Barrea L; Altieri B; Muscogiuri G; Laudisio D; Annunziata G; Colao A; Faggiano A; Savastano S
Nutrients; 2018 Dec; 10(12):. PubMed ID: 30513732
[TBL] [Abstract][Full Text] [Related]
4. A practical nutritional guideline to manage neuroendocrine neoplasms through chronotype and sleep.
Muscogiuri G; Zanata I; Barrea L; Cozzolino A; Filice E; Messina E; Colao A; Faggiano A
Crit Rev Food Sci Nutr; 2023; 63(25):7546-7563. PubMed ID: 35285728
[TBL] [Abstract][Full Text] [Related]
5. Predictors of long-term outcome in patients with well-differentiated gastroenteropancreatic neuroendocrine tumors after peptide receptor radionuclide therapy with 177Lu-octreotate.
Ezziddin S; Attassi M; Yong-Hing CJ; Ahmadzadehfar H; Willinek W; Grünwald F; Guhlke S; Biersack HJ; Sabet A
J Nucl Med; 2014 Feb; 55(2):183-90. PubMed ID: 24434296
[TBL] [Abstract][Full Text] [Related]
6. APOBEC3B High Expression in Gastroenteropancreatic Neuroendocrine Neoplasms and Association With Lymph Metastasis.
Feng C; Zheng Q; Yang Y; Xu M; Lian Y; Huang J; Jiang Y
Appl Immunohistochem Mol Morphol; 2019 Sep; 27(8):599-605. PubMed ID: 30095460
[TBL] [Abstract][Full Text] [Related]
7. Vitamin D deficiency and tumor aggressiveness in gastroenteropancreatic neuroendocrine tumors.
Altieri B; Barrea L; Modica R; Bottiglieri F; de Cicco F; Muscogiuri G; Circelli L; Savarese G; Di Somma C; Savastano S; Colao A; Faggiano A
Endocrine; 2022 Feb; 75(2):623-634. PubMed ID: 34533768
[TBL] [Abstract][Full Text] [Related]
8. Craniopharyngioma, Chronotypes and Metabolic Risk Profile.
Di Somma C; Scarano E; Barrea L; Solari D; Riccio E; Arianna R; Cavallo LM; Romano F; Di Benedetto E; Rodriguez A; de Alteriis G; Colao A
Nutrients; 2021 Sep; 13(10):. PubMed ID: 34684445
[TBL] [Abstract][Full Text] [Related]
9. High VEGF serum values are associated with locoregional spread of gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
Cigrovski Berković M; Čačev T; Catela Ivković T; Marout J; Ulamec M; Zjačić-Rotkvić V; Kapitanović S
Mol Cell Endocrinol; 2016 Apr; 425():61-8. PubMed ID: 26805636
[TBL] [Abstract][Full Text] [Related]
10. Neuroendocrine Tumor Heterogeneity Adds Uncertainty to the World Health Organization 2010 Classification: Real-World Data from the Spanish Tumor Registry (R-GETNE).
Nuñez-Valdovinos B; Carmona-Bayonas A; Jimenez-Fonseca P; Capdevila J; Castaño-Pascual Á; Benavent M; Pi Barrio JJ; Teule A; Alonso V; Custodio A; Marazuela M; Segura Á; Beguiristain A; Llanos M; Martinez Del Prado MP; Diaz-Perez JA; Castellano D; Sevilla I; Lopez C; Alonso T; Garcia-Carbonero R
Oncologist; 2018 Apr; 23(4):422-432. PubMed ID: 29330208
[TBL] [Abstract][Full Text] [Related]
11. Chronotype and Adherence to the Mediterranean Diet in Obesity: Results from the Opera Prevention Project.
Muscogiuri G; Barrea L; Aprano S; Framondi L; Di Matteo R; Laudisio D; Pugliese G; Savastano S; Colao A; On Behalf Of The Opera Prevention Project
Nutrients; 2020 May; 12(5):. PubMed ID: 32397384
[TBL] [Abstract][Full Text] [Related]
12. Visceral Obesity and Metabolic Syndrome Are Associated with Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors.
Santos AP; Santos AC; Castro C; Raposo L; Pereira SS; Torres I; Henrique R; Cardoso H; Monteiro MP
Cancers (Basel); 2018 Aug; 10(9):. PubMed ID: 30150555
[TBL] [Abstract][Full Text] [Related]
13. Risk factors for gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs): a three-centric case-control study.
Feola T; Puliani G; Sesti F; Modica R; Centello R; Minotta R; Cannavale G; Di Meglio S; Di Vito V; Lauretta R; Appetecchia M; Colao A; Lenzi A; Isidori AM; Faggiano A; Giannetta E
J Endocrinol Invest; 2022 Apr; 45(4):849-857. PubMed ID: 35040099
[TBL] [Abstract][Full Text] [Related]
14. Metabolic disorders and gastroenteropancreatic-neuroendocrine tumors (GEP-NETs): How do they influence each other? An Italian Association of Medical Oncology (AIOM)/ Italian Association of Medical Diabetologists (AMD)/ Italian Society of Endocrinology (SIE)/ Italian Society of Pharmacology (SIF) multidisciplinary consensus position paper.
Natalicchio A; Faggiano A; Zatelli MC; Argentiero A; D'Oronzo S; Marrano N; Beretta GD; Acquati S; Adinolfi V; Di Bartolo P; Danesi R; Ferrari P; Gori S; Morviducci L; Russo A; Tuveri E; Montagnani M; Gallo M; Silvestris N; Giorgino F
Crit Rev Oncol Hematol; 2022 Jan; 169():103572. PubMed ID: 34954047
[TBL] [Abstract][Full Text] [Related]
15. [Clinicopathological features and multivariate analysis of prognostic factors for patients with gastroenteropancreatic neuroendocrine tumors].
Wang X; Song ZF; Yao WX; Pan CC; Xiang MF; Wang H
Zhonghua Yi Xue Za Zhi; 2013 May; 93(18):1411-4. PubMed ID: 24025507
[TBL] [Abstract][Full Text] [Related]
16. Real-world comparison of healthcare resource utilization and costs of [
Cox T; O'Connell M; Leeuwenkamp O; Palimaka S; Reed N
Curr Med Res Opin; 2022 Aug; 38(8):1305-1317. PubMed ID: 35418254
[TBL] [Abstract][Full Text] [Related]
17. Higher IL-6 peri-tumoural expression is associated with gastro-intestinal neuroendocrine tumour progression.
Pereira SS; Pereira R; Santos AP; Costa MM; Morais T; Sampaio P; Machado B; Afonso LP; Henrique R; Monteiro MP
Pathology; 2019 Oct; 51(6):593-599. PubMed ID: 31466863
[TBL] [Abstract][Full Text] [Related]
18. Assessment and State of Nutrition of Patients with Gastroenteropancreatic Neuroendocrine Neoplasms.
Kikut J; Jasińska A; Pobłocki J; Brodowski J; Małgorzata S
Nutrients; 2020 Jun; 12(7):. PubMed ID: 32630081
[TBL] [Abstract][Full Text] [Related]
19. Expression and Molecular Regulation of the Cox2 Gene in Gastroenteropancreatic Neuroendocrine Tumors and Antiproliferation of Nonsteroidal Anti-Inflammatory Drugs (NSAIDs).
Gao F; Zafar MI; Jüttner S; Höcker M; Wiedenmann B
Med Sci Monit; 2018 Nov; 24():8125-8140. PubMed ID: 30420588
[TBL] [Abstract][Full Text] [Related]
20. ONCOGENE PANEL SEQUENCING ANALYSIS IDENTIFIES CANDIDATE ACTIONABLE GENES IN ADVANCED WELL-DIFFERENTIATED GASTROENTEROPANCREATIC NEUROENDOCRINE TUMORS.
Tirosh A; Killian JK; Zhu YJ; Petersen D; Walling J; Mor-Cohen R; Neychev V; Stevenson H; Keutgen XM; Patel D; Nilubol N; Meltzer P; Kebebew E
Endocr Pract; 2019 Jun; 25(6):580-588. PubMed ID: 30865533
[No Abstract] [Full Text] [Related]
[Next] [New Search]